Journal of Clinical Oncology
Articles in this Issue
Impact of radiation interruption and associated factors on overall survival in head and neck cancer at Tikur Anbessa Specialized Hospital, Ethiopia.
e18058 Background: Unplanned interruption in radical radiotherapy for head and neck squamous cell carcinoma is associated...
Multi-modal quality improvement's impact on colorectal cancer screening among people experiencing homelessness at a safety-net clinic.
e23290 Background: Preventive cancer screening rates are low among people experiencing homelessness (PEH), contributing to...
Comorbidity-related medical expenditures and health outcomes in cancer patients.
1641 Background: Comorbidities are common among adults with cancer and necessitate effective medical management. However,...
Alternative therapeutic targets in patients treated with immune checkpoint inhibitors for advanced urothelial cancer: Real-world data of German comprehensive cancer centers (ATTICI biomarker study).
e16583 Background: Erdafitinib is the first targeted therapy for inoperable or metastatic urothelial carcinoma (mUC). Its...
Optimization of tumor-infiltrating lymphocyte (TIL) manufacturing in non-small cell lung cancer (NSCLC) using an IL-7/IL-15/IL-2 expansion protocol.
2559 Background: Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) is a promising strategy in non-small cel...
NRG-HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.
TPS6138 Background: Patients with early-stage oral cavity cancer (OCC; T1-2N0M0; AJCC 8th edition) have a 20-30% risk of o...
A rationally designed local delivery platform (OncoPLEX) for sustained docetaxel release to overcome therapeutic barriers in post-resection solid tumors and glioblastoma.
e15099 Background: Post-surgical recurrence is a leading cause of treatment failure in solid tumors, particularly glioblas...
An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).
108 Background: The ENZAMET trial established that adding enzalutamide (ENZ) to androgen deprivation therapy (ADT) improve...
A phase I/II clinical study of DOC1021 (dubodencel) dendritic cell immunotherapy for refractory melanoma.
TPS9602 Background: DOC1021 is an autologous dendritic cell (DC)-based immunotherapy. Loading of DC in tandem with both pa...
The use of complementary and alternative medicine in the Middle East for managing neutropenia in cancer patients: A systematic review and meta-analysis of randomized controlled trials.
e23411 Background: Neutropenia, a common life-threatening complication of systemic cancer therapies, heightens infection r...
Cardiovascular comorbidity burden and in-hospital outcomes in patients with lung cancer: A retrospective analysis.
e20111 Background: Patients with lung cancer have the highest prevalence of pre-existing cardiovascular disease and face t...
The clinical significance of <i>TET2</i> -driven clonal hematopoiesis ( <i>TET2</i> -CH) in ICI-treated melanoma patients.
9549 Background: Clonal hematopoiesis (CH) arises from age-related somatic mutations in hematopoietic stem cells and has b...
Format matters: Digital vs print delivery of a job retention intervention during breast cancer therapy.
11060 Background: Talking to Employers and Medical Staff about Work (TEAMWork) is an English/Spanish...
Phase I/II, first-in-human study of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma: Safety and early efficacy profiles.
4169 Background: Yttrium-90 microsphere selective internal radiation therapy (Y-90 SIRT) plays a significant role in the t...
A phase II study of perioperative cadonilimab (AK104) in patients with recurrent resectable head and neck squamous cell carcinoma.
2529 Background: Salvage surgery is standard of care for patients with recurrent, resectable head and neck squamous cell c...
Beyond survival: Understanding unmet needs among a diverse cohort of ovarian cancer survivors.
5578 Background: Improvements in therapy have resulted in a growing population of ovarian cancer survivors, with both inci...
A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the HER2-positive GC/GEJC cohort.
e16034 Background: BAT8010 is an ADC argeting HER2, while BAT1006 is a humanized monoclonal antibody targeting another epi...
Comparison of the toxicity profile of different ADT + ARPI combinations in prostate cancer (PC) patients (pts): A systematic review and meta-analysis.
e17020 Background: ARPI selection in PC pts is primarily guided by comorbidities and drug interactions. To date, there are...
Alirocumab plus cemiplimab in immuno-refractory metastatic NSCLC: A single-arm, multi-center, phase 2 study.
2619 Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (N...
Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.
e15525 Background: C-C chemokine receptor 5 (CCR5) is implicated in tumor progression, immune modulation, and metastatic b...
Efficacy and safety of enzalutamide (ENZA) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) and cardiometabolic comorbidities (CMDs) and/or related concomitant medications (meds): ARCHES post hoc.
5092 Background: In ARCHES, ENZA improved radiographic progression-free survival (rPFS; primary: data cutoff, Oct 14, 2018...
Carboplatin-based versus cisplatin-based induction-concurrent chemoradiotherapy with locoregionally advanced nasopharyngeal carcinoma: A multicenter, parallel-group, non-inferiority, randomized, phase 3 trial.
6004 Background: Cisplatin-based chemoradiotherapy has been the standard of care in locoregionally advanced nasopharyngeal...
Outcomes of patients with cancer admitted to a dedicated oncology service within a multisite home hospital program.
1504 Background: Home hospital programs deliver acute, inpatient-level care in patients’ homes, and many health systems ha...
PD-L1 upregulation as a reflection of distinct immune contexts in luminal and basal breast cancer.
1040 Background: PD-L1 immunohistochemistry (IHC) is an approved biomarker to select patients with metastatic triple-negat...
Real-world comparative outcomes of intensive induction with 7+3 plus midostaurin versus azacitidine, venetoclax, and gilteritinib in FLT3-mutated acute myeloid leukemia.
e18551 Background: FLT3-mutated acute myeloid leukemia (AML) is associated with aggressive disease biology and historicall...